Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14821987 | 0.96 | PDE10A (1.00) | PDE10A | |
| SCHEMBL14822224 | 0.96 | PDE10A (0.93) | PDE10A | |
| SCHEMBL14822211 | 0.96 | PDE10A (1.00) | PDE10A | |
| SCHEMBL14822312 | 0.92 | PDE10A (0.84) | PDE10A | |
| SCHEMBL14821989 | 0.92 | PDE10A (1.00) | PDE10A | |
| SCHEMBL14812077 | 0.91 | PDE10A (0.83) | PDE10A | |
| SCHEMBL14822001 | 0.91 | PDE10A (1.00) | PDE10A | |
| SCHEMBL14821997 | 0.90 | PDE10A (1.00) | PDE10A | |
| SCHEMBL14822437 | 0.88 | PDE10A (1.00) | PDE10A | |
| SCHEMBL9107086 | 0.88 | PDE10A (0.78) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758396-B1 | TRIAZOLOPYRIDINE COMPOUNDS AS PDE10A INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-03-29 | — | — | EP | disclosed |
| US-9227970-B2 | Triazolopyridine compounds | HOFFMANN-LA ROCHE, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150099735-A1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-04-09 | — | — | US | disclosed |
| US-8946427-B2 | Triazolopyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140303141-A1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2014-10-09 | — | — | US | disclosed |
| WO-2013041472-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PDE10A INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303141-A1 | TRIAZOLOPYRIDINE COMPOUNDS | PDE3A, PDE5A, PDE3B | PDE10A 5/4885 |
| US-20150099735-A1 | TRIAZOLOPYRIDINE COMPOUNDS | PDE3A, PDE5A, PDE3B | PDE10A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.